IHL 0.00% 4.1¢ incannex healthcare limited

Why did SIG feel the need to get in here ?identifying...

  1. 4,327 Posts.
    lightbulb Created with Sketch. 8385
    Why did SIG feel the need to get in here ?

    identifying opportunity for big returns

    42X
    synergistic combination of 2 already approved drug candidates .....
    BA/BE study to be conducted by CMAX to hit FDA data points
    116 patient recruitment to assess tolerability and pharmacokinetics
    this drug candidate has already demonstrated safety profile and efficacy in a phase II proof of concept
    IND application being readied for Q12023 - if approval granted then multi site phase II/III study commences in the first half of 2023both here and in the US (this gives big pharma the look in they are after) - puts it in their face if you will) across a 12 month treatment period...
    Bob is in place which is another critical development asset in place

    this is why 42X is the most advanced clinical asset in the IHL locker

    SIG?
    they know their return will come from big pharma moving on this asset - its as simple as that

    Remember Cann get hit up by Glaxo- Smith Kline in April this year?
    GSK see an opportunity to capitalise on an approved OTC cbd product in the S3 space.....GSK?? they are giants?
    they struck a deal with Cann for the data profile off the back of Canns' phase III trial of a cbd sleep capsule...
    GSK will get exclusive rights to the data and will also have first dibbs at setting up the deals for commercialisation here and overseas.

    https://hotcopper.com.au/data/attachments/4912/4912563-fa208b66f7c55b957bb7fcb40a0f27e9.jpg

    Big pharma have approached IHL?...my guess would be yes
    why has something not occurred on that front then?
    because this bod know that the more development you put into this regulatory space and 42X the more zeros' you can add to the back of any big pharma deal that may pop up....it really is this simple

    SIG - shrewd move
    strategic? - yeah - it allows JL and the team to push the data points hard and increase those zeros on the back of what big pharma will throw to get it ....by not having to limit what they do through cash mitigation

    get what?
    an approved osa treatment that is marketable globally - and possibly a first mover

    yeah - kinda think IHL would have had a few door knocks already from the bigger guys

    don't think now is the time to leave - think it is the time to accumulate at such a ridiculous price point

    all my speculation - and just another read on things - nothing more

    glah

    Last edited by Flectional: 14/12/22
 
watchlist Created with Sketch. Add IHL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.